SCHEMBL4152959

SCHEMBL4152959

Cc1ccccc1NC(=O)c1ccnc2[nH]c(-c3ccc(F)cc3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.49
MAPT P10636 3/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
GSK3A P49840 1/20 0.46
GAA P10253 2/20 0.44
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
LMNA P02545 3/20 0.44
ESR1 P03372 1/20 0.44
TNKS O95271 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161701 0.88 GSK3B (0.59) GSK3BMAPTGSK3ALMNAESR1
SCHEMBL8237367 0.88 GSK3B (0.49) GSK3BMAPTHSD17B10GSK3AGAA
SCHEMBL4161629 0.86 GSK3B (0.48) GSK3BMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL4157381 0.86 GSK3B (0.63) GSK3BMAPTHSD17B10GAALMNA
SCHEMBL4153416 0.86 GSK3B (0.47) GSK3BMAPTGSK3AGAALMNA
SCHEMBL4145763 0.85 GSK3B (0.53) GSK3BGSK3AGAAMGAMSI
SCHEMBL4152144 0.84 GSK3B (0.60) GSK3BMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL13778140 0.84 GSK3B (0.55) GSK3BGSK3ALMNAESR1PTK2
SCHEMBL4148346 0.84 RAB9A (0.53) GSK3BMAPTHTTHPGDKMT2A
SCHEMBL4157512 0.84 GSK3B (0.53) GSK3BMAPTGSK3AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885MAPT 119/4885HSD17B10 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.